Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Randomization Required: Liver Signal Necessitated Kadcyla Trial With Control Arm

Apr 16 2013

• By Bridget Silverman

Related Content

Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

Aug 30 2010

<em>Erivedge</em> Efficacy Overcomes Limitations Of Single-Arm Study

Nov 01 2012

Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris

Aug 19 2011

Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says

Feb 08 2011

Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File

May 01 2011

<i>Adcetris</i> Review Adds Some Clarity To Principles For Accelerated Approval

Jul 25 2011

Related Companies

Genentech, Inc.

ImmunoGen, Inc.

Roche Holding AG

Novartis AG

Seagen Inc.

Takeda Pharmaceutical Co. Ltd.

Curis, Inc.

Additional Topics

Clinical Trials Regulation BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window